Thank you, Mr. Chair.
Dr. Kalyan, I'm wondering if there's a financial aspect to this in terms of why we're not proceeding with whole vaccines. Is there any financial aspect to that, specifically with respect to the ability to patent or profit off of whole vaccines versus, say, mRNA vaccines?